Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Adults With Sepsis
NCT06473844Recruiting
- Sponsor
- Hospital Authority
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in sepsis comparing Empagliflozin with Placebo (2 arms). Primary endpoints: 28-day mortality and Change in Sequential Organ Failure Assessment (SOFA) score at Day 7. Started Mar 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT06473844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06473844.